Pharmacological inhibition of MAP3K8 was reported to block human cytotoxic T lymphocyte effector functions [52] and may be therapeutically explored in the treatment of NASH. The gene discussed is MAP3K8; the disease is metabolic dysfunction-associated steatohepatitis.